Medtronic PLC $MDT Shares Acquired by Kingswood Wealth Advisors LLC

Key Points

• Kingswood Wealth Advisors increased its Medtronic stake by 238.7% in Q4, buying 13,634 shares to hold 19,345 shares valued at $1.858 million.
• Medtronic slightly beat quarterly estimates with EPS of $1.36 versus $1.34 and revenue of $9.02 billion versus $8.89 billion, and set FY2026 guidance of 5.620–5.660 EPS.
• Strategic momentum: Medtronic completed the CathWorks deal, invested in AI heart-care and saw first commercial use of the Stealth AXiS Autopilot surgical robot, and declared a quarterly dividend of $0.71 (annualized yield ~3.4%).

Kingswood Wealth Advisors LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 238.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,345 shares of the medical technology company's stock after buying an additional 13,634 shares during the period. Kingswood Wealth Advisors LLC's holdings in Medtronic were worth $1,858,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MDT. State Street Corp increased its position in shares of Medtronic by 1.0% during the 3rd quarter. State Street Corp now owns 60,460,537 shares of the medical technology company's stock valued at $5,800,550,000 after purchasing an additional 625,992 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Medtronic by 0.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 21,468,260 shares of the medical technology company's stock worth $2,044,637,000 after buying an additional 192,410 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Medtronic by 0.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 21,086,499 shares of the medical technology company's stock worth $2,008,278,000 after buying an additional 98,220 shares in the last quarter. Raymond James Financial Inc. raised its stake in shares of Medtronic by 3.0% in the 3rd quarter. Raymond James Financial Inc. now owns 11,203,865 shares of the medical technology company's stock worth $1,067,055,000 after buying an additional 327,899 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Medtronic by 35.3% in the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company's stock worth $970,456,000 after buying an additional 2,658,981 shares in the last quarter. Institutional investors own 82.06% of the company's stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Completed CathWorks deal and new investment broaden Medtronic’s AI heart-care footprint (adds AI coronary diagnostics; also led a $100M investment in Pulnovo) — accelerates higher-margin, software-enabled offerings that can lift long-term growth. Read More.
• Positive Sentiment: Commercial progress: first surgeons have used the Stealth AXiS Autopilot surgical robotic platform — marks a tangible commercialization milestone for Medtronic’s robotics strategy and could support procedure volume and recurring revenue. Read More.
• Positive Sentiment: Investor interest in strategic moves — coverage noting a new GE HealthCare tie-up and Altaviva launch alongside M&A/launch activity has drawn attention to potential catalysts for re-rating if momentum continues. Read More.
• Neutral Sentiment: Analyst stance: Jefferies reiterated a Hold and says portfolio streamlining (including the diabetes spin-off) has benefits but is offset by a lower growth outlook and valuation compression — supports cautious investor positioning. Read More.
• Neutral Sentiment: UBS trimmed its price target to $90 from $104 and maintains a neutral rating — near-term analyst-driven cap on upside until execution or guidance surprises. Read More.
• Neutral Sentiment: Industry tailwinds: multiple market reports name Medtronic as a leading player in catheters, home/long-term care devices, and automated insulin-delivery systems — underscores TAM exposure but not immediate earnings impact. Read More.
• Neutral Sentiment: Corporate recognition: Medtronic’s CISO was honored at the HoustonCISO ORBIE Awards — positive PR but limited direct stock impact. Read More.
• Negative Sentiment: Share weakness and volatility: recent coverage highlights a notable YTD decline and short-term selloffs, which can pressure multiples and invite further analyst scrutiny if momentum doesn’t recover. Read More.
• Negative Sentiment: Recent daily dip: headlines note a larger-than-market intraday move downward in recent sessions — reinforcing near-term investor caution. Read More.

Medtronic Price Performance

NYSE MDT opened at $83.80 on Friday. The stock has a market capitalization of $107.59 billion, a P/E ratio of 23.34, a P/E/G ratio of 2.16 and a beta of 0.75. Medtronic PLC has a 1 year low of $79.93 and a 1 year high of $106.33. The business's fifty day moving average is $90.10 and its two-hundred day moving average is $95.36. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts' expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.4%. Medtronic's dividend payout ratio is currently 79.11%.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company's stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.26% of the company's stock.

Analyst Ratings Changes

MDT has been the topic of a number of research reports. Barclays boosted their price objective on Medtronic from $118.00 to $120.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 1st. Daiwa Securities Group dropped their price objective on Medtronic from $117.00 to $115.00 and set a "buy" rating on the stock in a research note on Friday, February 27th. Mizuho dropped their price objective on Medtronic from $125.00 to $120.00 and set an "outperform" rating on the stock in a research note on Monday, April 13th. Sanford C. Bernstein boosted their price objective on Medtronic from $111.00 to $112.00 and gave the stock an "outperform" rating in a research note on Friday, January 9th. Finally, Leerink Partners reissued an "outperform" rating and issued a $119.00 price objective on shares of Medtronic in a research note on Tuesday, March 10th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Medtronic presently has an average rating of "Moderate Buy" and an average price target of $107.80.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.